Developmental funds have been used for two purposes during the last grant cycle and we propose to continue funding in these areas in the next grant cycle. 1) Pilot Funds - The CCSG developmental funds support three types of pilot grants, each targeting a different Cancer Center member group: ? Push grants - to accelerate (or """"""""push"""""""") the pace of effort on cancer-focused research initiatives judged to have a high potential to lead to peer-reviewed funding within 1 -2 years. Pull grants - to encourage cancer research among non-cancer members and new members, i.e. to """"""""puir them into the Cancer Center. Paff/7er grants - to encourage clinicians to partner with a basic or population scientist in a joint project in translational research. Partner grants require matching funds from the clinical department. These pilot grants have yielded a return of investment of about 14 fold over the past five years. We plan to continue using these pilot project mechanisms in the next grant cycle. 2) Shared Resource Development - We have used CCSG developmental funds from the past grant cycle to support our Crystallography and Computational Biosciences (CCB) shared resource. This shared resource was originally proposed in our last competing renewal and is now requested as a full shared resource. In the new grant cycle, we propose funding for two developing shared resources: Synthetic Chemistry and Translational Imaging. In addition to continuing funding for these two areas, we propose adding bridge funding support in the next grant cycle.
Developmental funds provide a key source of support for the strategic and programmatic priorities and scientific opportunities of our Center as identified through our planning and evaluation processes. These funds provide the opportunity to explore innovative pilot projects, new collaborations and new technologies.
|Park, Sun H; Keller, Evan T; Shiozawa, Yusuke (2018) Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis. Calcif Tissue Int 102:152-162|
|Haas, Karen M; Johnson, Kristen L; Phipps, James P et al. (2018) CD22 Promotes B-1b Cell Responses to T Cell-Independent Type 2 Antigens. J Immunol 200:1671-1681|
|Suo, Xubin; Eldridge, Brittany N; Zhang, Han et al. (2018) P-Glycoprotein-Targeted Photothermal Therapy of Drug-Resistant Cancer Cells Using Antibody-Conjugated Carbon Nanotubes. ACS Appl Mater Interfaces 10:33464-33473|
|Widner, D Brooke; Park, Sun H; Eber, Matthew R et al. (2018) Interactions Between Disseminated Tumor Cells and Bone Marrow Stromal Cells Regulate Tumor Dormancy. Curr Osteoporos Rep 16:596-602|
|Liu, Liang; Ruiz, Jimmy; O'Neill, Stacey S et al. (2018) Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1. Mol Cancer 17:81|
|Sirkisoon, Sherona R; Carpenter, Richard L; Rimkus, Tadas et al. (2018) Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer. Oncogene 37:2502-2514|
|Goyal, Amrita; Carter, Joi B; Pashtan, Itai et al. (2018) Very low-dose versus standard dose radiation therapy for indolent primary cutaneous B-cell lymphomas: A retrospective study. J Am Acad Dermatol 78:408-410|
|Su, Weijun; Hong, Lixin; Xu, Xin et al. (2018) miR-30 disrupts senescence and promotes cancer by targeting both p16INK4A and DNA damage pathways. Oncogene 37:5618-5632|
|Miller Jr, David P; Denizard-Thompson, Nancy; Weaver, Kathryn E et al. (2018) Effect of a Digital Health Intervention on Receipt of Colorectal Cancer Screening in Vulnerable Patients: A Randomized Controlled Trial. Ann Intern Med 168:550-557|
|Rimkus, Tadas K; Carpenter, Richard L; Sirkisoon, Sherona et al. (2018) Truncated Glioma-Associated Oncogene Homolog 1 (tGLI1) Mediates Mesenchymal Glioblastoma via Transcriptional Activation of CD44. Cancer Res 78:2589-2600|
Showing the most recent 10 out of 548 publications